FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors

Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US.
News Alerts

source https://www.medscape.com/viewarticle/973228?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost